Report Description Table of Contents Introduction And Strategic Context The Global Neoantigen Targeted Therapy Market is projected to expand at a remarkable growth rate, estimated at USD 1.9 billion in 2024 and expected to reach USD 8.5 billion by 2030, registering a CAGR of 28.4% according to Strategic Market Research. Neoantigen targeted therapy reflects a transformative leap in personalized oncology, leveraging tumor-specific mutations to develop custom immunotherapies tailored to each patient. Neoantigens—unique proteins arising from somatic mutations—enable highly selective immune activation against cancer cells while minimizing harm to healthy tissues. Positioned at the intersection of immunotherapy, genomics, and AI-driven diagnostics, this therapy model represents one of the most promising frontiers in precision cancer care. Several macro forces are shaping market acceleration through 2030: Falling Sequencing Costs: Rapid declines in next-generation sequencing expense are making tumor mutation profiling more accessible to oncology centers worldwide. Limitations of Current Immunotherapies: Growing clinical fatigue around conventional checkpoint inhibitors, especially in refractory or relapsed patients, is increasing demand for more personalized immune interventions. Pressure for True Personalized Medicine: Pharma companies face rising expectations to deliver mutation-specific rather than tumor-type-specific therapies, reshaping R&D direction. Regulatory agencies such as the FDA and EMA are taking proactive roles, granting accelerated review pathways for neoantigen-based therapies in indications including melanoma, NSCLC, and glioblastoma. Investor enthusiasm remains high, with multiple biotech startups raising nine-figure funding rounds based on platform potential and early-phase clinical data. Biotech Innovators developing mRNA vaccines, dendritic cell platforms, and engineered T-cell therapies. Pharmaceutical Firms collaborating with genomic analytics providers to optimize patient selection and antigen prediction. Hospitals & Cancer Centers expanding sequencing and immunology infrastructure to support personalized therapy workflows. CROs and CDMOs refining rapid manufacturing pipelines for autologous oncology products. Neoantigen therapy is rapidly evolving from experimental concept to core component of next-generation precision oncology. As outcome-based care expands, the ability to design therapies directly from an individual’s tumor genomics is becoming not only scientifically feasible but clinically inevitable. Market Segmentation And Forecast Scope The neoantigen targeted therapy market is segmented across therapy type, cancer indication, delivery platform, end user, and geography. These dimensions highlight how personalized immunotherapy is aligning with scalable oncology care models. By Therapy Type Personalized Neoantigen Vaccines: Custom-designed peptide or mRNA vaccines built from a patient’s tumor mutation profile to trigger targeted immune activation. T-cell Based Therapies: Engineered T-cells, including TCR-modified platforms, designed to recognize patient-specific neoantigens and overcome tumor heterogeneity. In 2024, personalized vaccines represent over 60% of clinical trial activity, while T-cell therapies are gaining traction, particularly in high-mutation solid tumors requiring deeper immune responses. By Cancer Indication Melanoma: Represents an estimated 36% of active neoantigen trials due to high mutational load and strong immunogenicity. Non-Small Cell Lung Cancer (NSCLC): A major growth area driven by unmet need in checkpoint-refractory patient populations. Glioblastoma: Explored for its potential to bypass the blood-brain barrier and induce localized immune responses. Bladder Cancer: Growing adoption in combination vaccine trials, especially post-checkpoint inhibitor exposure. Colorectal & Other Cancers: Expanded by advances in prediction algorithms and immune profiling. Melanoma and NSCLC are primary market drivers, but colorectal and glioblastoma programs are accelerating due to improved biomarker strategies and computational tools. By Delivery Platform mRNA: The dominant modality in 2024, accounting for rapid manufacturing and adaptability validated during the COVID-19 era. Peptide-Based: Low-cost and simple but challenged by immunogenicity variability. Dendritic Cell-Based: Effective for difficult tumors but limited in scalability. DNA-Based (Plasmid): Niche but promising for multi-antigen delivery and long-term expression. mRNA is expected to account for over 70% of new vaccine trials by 2025. By End User Academic Medical Centers: Lead adopters with sequencing and immunology infrastructure to support individualized workflows. Specialty Cancer Hospitals: Increasing investment in biopsy-to-therapy infrastructure and genomic integration. Community Oncology Networks: Early-stage participants beginning to contribute through referrals and remote sampling. Neoantigen therapies are primarily delivered in academic and specialty settings, with decentralized models expected to expand access over time. By Region North America: Largest and most mature market with leadership in clinical trials, mRNA development, and regulatory flexibility. Europe: Strong R&D presence, particularly in Germany, the U.K., and the Netherlands. Asia Pacific: Fastest-growing region led by China, Japan, and South Korea. Latin America: Early-stage adoption, with selective participation in international trials. Middle East & Africa: Emerging interest but limited by early-stage regulatory and sequencing infrastructure. Asia Pacific is expected to surpass Europe in trial volume by 2030, while North America maintains commercialization leadership. Market Trends And Innovation Landscape The neoantigen targeted therapy market is entering a phase where speed, precision, and scalability are becoming just as critical as scientific novelty. From 2024 to 2030, innovation in this space is not only reshaping how immunotherapies are designed—it’s also redefining how cancer care is delivered, one patient at a time. AI-Powered Neoantigen Prediction Is Becoming the Core Engine One of the most transformative shifts is the integration of AI in antigen selection pipelines. What used to take months—analyzing tumor mutations, identifying candidate neoantigens, ranking them by immunogenicity—is now being compressed into a few weeks, thanks to machine learning models trained on tumor genomes and immune response datasets. These AI tools don’t just automate; they optimize. They help researchers filter out weak targets, prioritize clonal neoantigens, and even predict cross-patient reactivity. In aggressive cancers like glioblastoma or metastatic NSCLC, where treatment windows are tight, this speed can mean the difference between trial eligibility and disease progression. Combination Therapies Are Redefining Immune Synergy Monotherapies are no longer the gold standard. The new norm is strategic pairing—neoantigen vaccines or T-cell therapies administered alongside checkpoint inhibitors like anti-PD-1 or CTLA-4 antibodies. Early-phase trials are showing heightened T-cell activation and improved tumor control in combination settings. The underlying logic is simple: checkpoint inhibitors remove immune system brakes, while neoantigens step on the gas. Together, they’re turning “cold” tumors into “hot” ones—and that’s opening doors in cancers that historically showed limited response. This is especially promising in melanoma, bladder cancer, and microsatellite stable colorectal cancer, where solo checkpoint inhibitors have had mixed outcomes. Platform Engineering Is Creating Second-Generation Modalities The mRNA platforms that gained trust during the pandemic are now being re-engineered for oncology. Developers are introducing self-amplifying RNA (saRNA) formats that require lower doses but achieve longer antigen expression. This not only reduces manufacturing burden—it also improves immune engagement. On the delivery side, lipid nanoparticle (LNP) systems are being optimized for oncology use. These aren't the same LNPs used for infectious disease vaccines. They're being tailored to target immune cells, reduce off-target effects, and improve tumor-site accumulation. Meanwhile, in the T-cell space, some companies are experimenting with off-the-shelf neoantigen receptor libraries. Instead of building a fully personalized therapy each time, these libraries offer pre-validated TCR options for recurrent mutation profiles. This could dramatically shorten production cycles—a major hurdle for cell-based therapies today. Adaptive Trial Designs and Regulatory Flexibility Are Gaining Ground Traditional clinical trial frameworks don’t work well for patient-specific therapies. Regulators have taken note. The FDA and EMA are now supporting adaptive designs that group patients by mutation profile rather than tumor type—allowing cross-indication data pooling. This is especially helpful in rare mutations where enrollment numbers are low, but clinical need is high. Some agencies are also issuing individualized therapy guidance—allowing case-by-case review and conditional approvals based on immune response markers, not just tumor shrinkage. The net effect? Faster regulatory cycles, more trial launches, and earlier patient access, particularly in the U.S., U.K., and Germany. Strategic Partnerships Are Accelerating the Ecosystem Nobody in this market is doing it alone. Big pharma is leaning heavily on biotech firms for innovation, while startups are relying on academic centers and cloud-based data providers to scale. Several high-profile alliances have emerged: Biotechs are embedding AI antigen prediction tools into sequencing pipelines. CDMOs are building dedicated GMP lines for fast-turnaround mRNA vaccine batches. Hospitals are working directly with tech firms to integrate genomic data with electronic health records for streamlined trial enrollment. What’s emerging is a distributed but tightly integrated network—from biopsy to bedside. Real-Time Therapy Adjustment Is on the Horizon One of the most forward-looking trends is the concept of dynamic neoantigen therapy. Instead of a one-time vaccine or cell product, developers are exploring longitudinal antigen tracking—adjusting therapy as the tumor evolves. This requires serial biopsies, real-time sequencing, and fast re-manufacturing loops. While still experimental, this approach could help prevent tumor escape and extend progression-free survival—especially in genetically unstable cancers. Experts believe that this “living therapy” model will define the next generation of personalized immunotherapy—where treatment doesn’t just match the patient, but evolves with the disease. Bottom Line? Neoantigen therapy is no longer just about scientific precision—it’s about logistical execution, data integration, and clinical adaptability. The companies and institutions leading the charge are the ones engineering for scale—not just in manufacturing, but in patient matching, regulatory navigation, and treatment evolution. This isn’t a static field—it’s a dynamic race. And the winners will be those who can turn personalized science into personalized systems of care. Competitive Intelligence And Benchmarking The neoantigen targeted therapy space is highly competitive but still early in its maturation curve. What makes this landscape unique isn’t just who has the deepest pipelines—but who can integrate genomics, AI, manufacturing, and immunology into one cohesive, scalable platform. Speed, precision, and customization define the winners. Moderna Moderna is setting the pace in personalized mRNA-based neoantigen vaccines. In collaboration with Merck, the company reported positive Phase 2b results for its mRNA-4157/V940 vaccine in high-risk melanoma patients when paired with pembrolizumab. The program has now entered Phase 3, making it one of the most clinically advanced assets in the field. Moderna's edge lies in its proven mRNA manufacturing capabilities and ability to pivot quickly between infectious disease and oncology pipelines. Its modular vaccine design and cloud-based trial infrastructure give it a clear commercialization advantage. BioNTech BioNTech is leveraging its iNeST (individualized neoantigen specific immunotherapy) platform across several solid tumor indications. Its expanded partnership with the UK government aims to enroll up to 10,000 patients in personalized vaccine trials by 2030. It also benefits from legacy IP and manufacturing experience from COVID-19 vaccines. What sets BioNTech apart is its end-to-end ecosystem—from tumor sequencing to final vaccine delivery—paired with a growing presence in both the EU and U.S. markets. Its combination of AI-enabled antigen selection and rapid mRNA design is helping it maintain leadership in early-phase trial execution. Gritstone Bio Gritstone is developing self-amplifying RNA (saRNA) neoantigen vaccines, offering lower dose requirements and longer antigen expression. Its Phase 2 colorectal cancer trial, backed by the U.S. National Cancer Institute, places it among the few with both platform innovation and institutional validation. Gritstone’s unique advantage is its dual-pillar platform: combining AI-powered neoantigen selection with next-gen RNA constructs. This dual approach may yield stronger immune responses while reducing manufacturing costs—a critical differentiator as the field moves toward commercial scalability. Achilles Therapeutics Achilles is pioneering T-cell therapies based on clonal neoantigens—mutations shared across all tumor cells, not just a subset. Its CHIRON (NSCLC) and THETIS (melanoma) trials have shown early signs of durable immune responses and tumor shrinkage. Achilles’ clonal targeting strategy tackles tumor heterogeneity head-on. Though still in early clinical stages, this science-led approach may prove crucial in avoiding relapse due to antigen escape. Its in-house manufacturing pipeline adds to its long-term scalability potential. Nouscom Nouscom is advancing both off-the-shelf and personalized neoantigen vaccines. Its recent €67.5 million Series C financing will fund upcoming Phase 1/2 trials in hard-to-treat solid tumors. The company is also exploring viral vector delivery, setting it apart from pure mRNA players. Nouscom’s versatility across vaccine formats—coupled with strong European investor backing—positions it as a rising challenger, particularly in combination regimens and tumor types with fewer treatment options. Emerging Innovators Neon Therapeutics, now part of BioNTech, helped lay the groundwork for AI-driven neoantigen selection algorithms—many of which are still core to BioNTech’s pipeline today. Personalis and Geneos Therapeutics are combining tumor exome sequencing and custom vaccine design, offering modular, service-based models that could scale to mid-tier oncology centers. Big Pharma’s Role While most Big Pharma firms haven’t built internal neoantigen engines, many are aggressively partnering: Roche/Genentech is collaborating with BioNTech and other early-stage firms on both peptide- and mRNA-based neoantigen vaccines. AstraZeneca and Pfizer are exploring T-cell-based neoantigen approaches, often through licensing or academic alliances. Big Pharma’s strategy is clear: avoid building from scratch. Instead, support biotech innovation and lock in pipeline access through co-development or M&A. Regional Players and Expansion In China, firms like Shuwen Biotech and GeneCast are investing in in-house neoantigen discovery pipelines, often supported by government-led genomic initiatives. South Korean biotech firms, backed by tech conglomerates and medtech innovation funds, are entering early trials for mRNA-based neoantigen therapies. Benchmarking Summary Company Primary Focus Platform Strength Clinical Stage Key Advantage Moderna mRNA vaccine + checkpoint combo Scalable mRNA + proven trial execution Phase 3 Regulatory head start and global trial presence BioNTech mRNA iNeST pipeline End-to-end personalization Multiple Phase 1/2 Full-stack development, global government alliances Gritstone Bio saRNA vaccines AI + next-gen RNA Phase 2 (CRC) Lower dosing, fast antigen delivery Achilles T-cell therapy with clonal targeting Precision T-cell engineering Early Phase 1/2 Tackles tumor heterogeneity at source Nouscom Off-the-shelf & personalized vaccines Viral vector platform Pre-Phase 2 Strong in hard-to-treat tumors and combination trials Final Insight This isn’t a market defined by blockbuster drugs—yet. It’s defined by platform architecture, turnaround speed, and clinical personalization. The next market leaders will be those who scale AI, manufacturing, and regulatory readiness in one seamless loop. Regional Landscape And Adoption Outlook Adoption of neoantigen targeted therapy varies widely by region, influenced by healthcare infrastructure, regulatory flexibility, genomic sequencing capacity, and investment ecosystems. While innovation is global, early access and scale-up remain highly concentrated in a few countries. North America North America, particularly the United States, dominates the global landscape. The region accounts for the majority of active clinical trials and houses several of the key players driving both vaccine and T-cell-based development. What gives the U.S. a strategic edge is its combination of advanced sequencing infrastructure, flexible regulatory frameworks (like the FDA’s accelerated approval pathways), and deep capital markets. Top-tier cancer centers such as MD Anderson, Memorial Sloan Kettering, and Dana-Farber are actively running investigator-sponsored trials and collaborating with biotech firms. The U.S. is also a hotspot for biotech–pharma collaborations, which are essential for personalized platforms that require integration across data, diagnostics, and delivery. Europe Europe is not far behind. Germany, the United Kingdom, and the Netherlands are emerging as hubs for mRNA-based research and early-phase manufacturing. Germany in particular benefits from a strong precision medicine ecosystem, bolstered by companies like BioNTech and CureVac. The U.K.'s NHS Genomic Medicine Service is starting to make patient-level tumor sequencing more routine, laying the foundation for broader neoantigen-based trial participation. That said, reimbursement models in Europe remain conservative. While academic institutions are pushing forward, wide commercial rollout will likely lag behind the U.S. unless pricing frameworks adapt to individualized therapies. Asia Pacific Asia Pacific is growing rapidly, with China and South Korea leading the charge. In China, companies are entering early-stage trials supported by state-backed initiatives to boost precision oncology. The country’s genomic infrastructure has expanded dramatically, and some local players are exploring in-house neoantigen prediction engines. South Korea’s strong medical technology base and universal healthcare system have made it an attractive site for multinational trials. Japan, although more conservative in clinical adoption, is showing increased interest through collaborations with Western biotech firms. Latin America And The Middle East & Africa Latin America And The Middle East & Africa represent largely untapped markets. The biggest barrier here is infrastructure—both in terms of genomic sequencing capabilities and customized therapy logistics. A lack of regulatory frameworks for highly personalized treatments further limits early adoption. That said, as costs fall and cloud-based data sharing improves, some large oncology centers in Brazil and the UAE are beginning to explore participation in international trials. Regionally, white space opportunities lie in underserved patient populations, especially where standard-of-care options have failed. In these settings, personalized immunotherapy—though complex—may be one of the few viable paths to durable remission. Experts point out that global expansion won’t just be about licensing; it will require building clinical, digital, and regulatory capabilities tailored to each region’s infrastructure. The bottom line: neoantigen therapy is still largely a North American and European story, but the seeds of future growth are being planted across Asia Pacific and beyond. The pace at which these regions adapt will shape the market’s trajectory over the next five years. End-User Dynamics And Use Case Neoantigen targeted therapies are not plug-and-play solutions—they require an ecosystem that integrates genomic sequencing, immunology, clinical oncology, and highly personalized manufacturing workflows. This makes the end-user landscape both narrow and technically demanding, dominated by a select group of specialized providers. Academic Medical Centers These institutions form the operational backbone of neoantigen therapy deployment. Centers like Dana-Farber, MD Anderson, and Gustave Roussy possess the genomic infrastructure, multidisciplinary care teams, and trial experience required to design and execute individualized treatment plans. In many cases, these centers are not just administering therapy—they're co-developing it. Their ability to conduct tumor profiling, interpret immunogenicity predictions, and monitor adaptive responses places them at the core of the early adoption curve. Specialty Cancer Hospitals High-volume cancer hospitals affiliated with research universities or national health systems are the next wave of adopters. These facilities are investing in in-house bioinformatics and tumor sequencing labs to support participation in neoantigen trials. Some, like leading centers in Germany, the U.K., and South Korea, are already restructuring clinical teams to include molecular pathologists, data scientists, and immunotherapy specialists. These changes reflect a growing commitment to precision oncology pathways. Pharmaceutical Partners and CROs While not end users in the traditional sense, pharma companies and CROs are deeply embedded in this delivery chain. Drug sponsors frequently provide training, manufacturing support, and clinical data tools to end-user sites. Contract research organizations manage complex logistics for sample collection, sequencing, therapy production, and patient follow-up, especially for multi-site and international trials. As therapy customization becomes the norm, CROs are evolving into operational enablers of point-of-care personalization. Integrated Oncology Networks In North America and parts of Europe, integrated cancer care networks are beginning to test hybrid models that bring tumor profiling, therapy selection, and patient monitoring under one roof. These setups are ideal for scaling neoantigen therapies beyond elite research hospitals—offering a potential blueprint for wider clinical adoption over the next 3–5 years. Use Case Highlight: South Korea's Rapid Personalization Model A leading tertiary cancer center in South Korea treated a 53-year-old male with recurrent non-small cell lung cancer, unresponsive to checkpoint inhibitors and platinum-based chemotherapy. The care team performed whole-exome and transcriptome sequencing to identify clonal neoantigens shared across all tumor sites. An mRNA-based personalized vaccine was designed in partnership with a biotech firm and administered alongside pembrolizumab. Within three months, the patient showed reduced tumor burden, increased circulating neoantigen-specific T-cell levels, and improved progression-free survival. What made this case notable was not just the outcome, but the turnaround time: less than five weeks from biopsy to first dose, thanks to coordinated workflows between the hospital, sequencing lab, and manufacturer. The success prompted the institution to develop a formal “Neoantigen Fast Track” protocol for other high-risk patients. Ecosystem Readiness: A Bottleneck or a Bridge? Scaling neoantigen therapy beyond elite centers depends on how quickly healthcare systems can evolve operationally. Current barriers include: Inconsistent access to tumor sequencing Lack of integrated digital platforms to track patient-specific data High staff training requirements across oncology, pathology, and immunology But the trend is clear: providers who invest in multidisciplinary teams and workflow digitization will be first in line for early access programs and partnerships with therapy developers. That alone could drive competitive differentiation at the care delivery level. Bottom line? This isn’t just a scientific challenge—it’s a systems challenge. Neoantigen therapy will test the operational maturity of every hospital that wants to offer it. Recent Developments + Opportunities & Restraints Recent Developments (Last 2 Years) Moderna and Merck reported positive Phase 2b melanoma results for mRNA-4157/V940 in combination with pembrolizumab. BioNTech expanded its U.K. collaboration to support up to 10,000 personalized vaccine treatments by 2030. Gritstone Bio initiated a Phase 2 colorectal cancer study using saRNA neoantigen platforms. Achilles Therapeutics released encouraging NSCLC and melanoma T-cell response data from CHIRON and THETIS trials. Nouscom secured €67.5M to advance off-the-shelf and personalized vaccine pipelines. Opportunities Early-stage cancer applications enabling adjuvant therapy and recurrence prevention. AI-driven personalization through improved antigen prediction and real-time immune profiling. Emerging genomic hubs in China, South Korea, and the UAE opening new clinical markets. Restraints High costs and scalability issues tied to individualized manufacturing workflows. Regulatory uncertainty for per-patient therapies that fall outside conventional approval frameworks. Reimbursement challenges due to personalized pricing models. 7.1. Report Coverage Table Report Attribute Details Forecast Period 2024 – 2030 Market Size Value in 2024 USD 1.9 Billion Revenue Forecast in 2030 USD 8.5 Billion Overall Growth Rate CAGR of 28.4% (2024 – 2030) Base Year for Estimation 2024 Historical Data 2019 – 2023 Unit USD Million, CAGR (2024 – 2030) Segmentation By Therapy Type, By Cancer Indication, By Delivery Platform, By End User, By Geography By Therapy Type Personalized Neoantigen Vaccines, T-cell Based Therapies By Cancer Indication Melanoma, NSCLC, Glioblastoma, Bladder Cancer, Colorectal Cancer, Others By Delivery Platform mRNA, Peptide, Dendritic Cell, DNA-based By End User Academic Medical Centers, Specialty Cancer Hospitals By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, Germany, U.K., France, China, Japan, South Korea, Brazil, UAE Market Drivers • Increasing adoption of personalized cancer immunotherapy • Advancements in neoantigen prediction algorithms • Growing clinical evidence supporting neoantigen-based combinations Customization Option Available upon request Frequently Asked Question About This Report Q1: How big is the neoantigen targeted therapy market? A1: The global neoantigen targeted therapy market was valued at USD 1.9 billion in 2024. Q2: What is the CAGR for the forecast period? A2: The market is projected to grow at a CAGR of 28.4% from 2024 to 2030. Q3: Who are the major players in this market? A3: Leading players include Moderna, BioNTech, Gritstone Bio, Achilles Therapeutics, and Nouscom. Q4: Which region dominates the market share? A4: North America leads due to strong clinical infrastructure, sequencing capacity, and regulatory flexibility. Q5: What factors are driving this market? A5: Growth is driven by AI-enabled antigen selection, favorable clinical outcomes, and increasing investment in personalized cancer immunotherapy. Table of Contents – Global Neoantigen Targeted Therapy Market Report (2024–2030) Executive Summary Market Overview Market Attractiveness by Therapy Type, Cancer Indication, Delivery Platform, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Future Projections (2019–2030) Summary of Market Segmentation by Therapy Type, Cancer Indication, Delivery Platform, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Therapy Type, Cancer Indication, Delivery Platform, and End User Investment Opportunities in the Neoantigen Targeted Therapy Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Technological Factors Infrastructure and Workflow Limitations Global Neoantigen Targeted Therapy Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Therapy Type: Personalized Neoantigen Vaccines T-cell Based Therapies Market Analysis by Cancer Indication: Melanoma Non-Small Cell Lung Cancer (NSCLC) Glioblastoma Bladder Cancer Colorectal & Other Cancers Market Analysis by Delivery Platform: mRNA Peptide-Based Dendritic Cell-Based DNA-Based (Plasmid) Market Analysis by End User: Academic Medical Centers Specialty Cancer Hospitals Community Oncology Networks Market Analysis by Region: North America Europe Asia Pacific Latin America Middle East & Africa Regional Market Analysis North America Neoantigen Targeted Therapy Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Therapy Type, Cancer Indication, Delivery Platform, End User Country-Level Breakdown United States Canada Europe Neoantigen Targeted Therapy Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Therapy Type, Cancer Indication, Delivery Platform, End User Country-Level Breakdown Germany United Kingdom France Rest of Europe Asia Pacific Neoantigen Targeted Therapy Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Therapy Type, Cancer Indication, Delivery Platform, End User Country-Level Breakdown China Japan South Korea Rest of Asia Pacific Latin America Neoantigen Targeted Therapy Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Therapy Type, Cancer Indication, Delivery Platform, End User Country-Level Breakdown Brazil Mexico Rest of Latin America Middle East & Africa Neoantigen Targeted Therapy Market Analysis Historical Market Size and Volume (2019–2023) Market Size and Volume Forecasts (2024–2030) Market Analysis by Therapy Type, Cancer Indication, Delivery Platform, End User Country-Level Breakdown United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Moderna BioNTech Gritstone Bio Achilles Therapeutics Nouscom Competitive Landscape and Strategic Insights Benchmarking Based on Platform, Trial Stage, and Commercial Readiness Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Therapy Type, Cancer Indication, Delivery Platform, End User, and Region (2024–2030) Regional Market Breakdown by Segment Type (2024–2030) List of Figures Market Drivers, Challenges, and Opportunities AI Tools and Workflow Overview in Neoantigen Development Regional Market Penetration Snapshot Innovation Pipeline by Leading Companies Market Share by Therapy Type, Cancer Indication, Delivery Platform, and End User (2024 vs. 2030)